← Leaderboards
Abhijit Prakash Limaye
University Of Washington
$10,475,049
Attributed
$36,370,781
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.3M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,370,781 · 7
By mechanism
U01$21,380,266 · 2
UH3$8,723,851 · 1
R01$3,463,926 · 1
UG3$2,341,858 · 1
R21$460,500 · 1
M01$380 · 1
Top collaborators
- Michael J Boeckh10 shared
- Gordon D Rubenfeld10 shared
- Cynthia E Fisher9 shared
- Don J Diamond6 shared
- Renee D Stapleton6 shared
- Daniel Conlon Brennan3 shared
- Sayan Dasgupta3 shared
- Corinna La Rosa2 shared
Most similar at University Of Washington
Same institution · by research overlap
- Geoffrey Scott Gottlieb$16,750,227
- Anna Wald$34,443,936
- Robert W. Coombs$29,428,054
- Cynthia E Fisher$6,512,207
- James Ivan Mullins$34,901,920
Others in their field
Top investigators on “Cytomegalovirus”
- Constance Ann Benson · University Of California, San Diego$154,530,762
- Curtis L Meinert · Johns Hopkins University$72,267,482
- Louis J. Picker · Oregon Health And Science University$67,787,971
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Dan H. Barouch · Fred Hutchinson Cancer Center$34,316,808
- Jay A Nelson · Oregon Health & Science University$28,085,685
Research focus
CytomegalovirusCytomegalovirus InfectionsMorbidity - Disease RateProphylactic TreatmentPreventionOrganImmuneViral Load ResultPreventMortalitySeropositiveAdultValganciclovirVirusLungSafetyTransplant RecipientsRandomized Placebo Controlled TrialDouble-Blind MethodClinically RelevantMulti-Institutional Clinical TrialAntigensLiver TransplantationFunctional Disorder
Grant awards (22)
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$3,209,830
U01 · FY2025 · AI · contact PI
Kidney transplant Preemptive therapy or Prophylaxis (KPoP) for CMVPreventionin D+R- Recipients$1,698,522
R01 · FY2025 · AI · contact PI
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$2,672,910
U01 · FY2024 · AI · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,170,027
UH3 · FY2024 · HL
Kidney transplant Preemptive therapy or Prophylaxis (KPoP) for CMVPreventionin D+R- Recipients$1,254,477
R01 · FY2024 · AI · contact PI
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$658,822
U01 · FY2024 · AI · contact PI
Kidney transplant Preemptive therapy or Prophylaxis (KPoP) for CMV Preventionin D+R- Recipients$510,927
R01 · FY2024 · AI · contact PI
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$3,331,802
U01 · FY2023 · AI · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,120,121
UH3 · FY2023 · HL
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$3,354,504
U01 · FY2022 · AI · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,216,758
UH3 · FY2022 · HL
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT)$2,295,742
U01 · FY2021 · AI · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$1,503,461
UH3 · FY2021 · HL
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$713,484
UH3 · FY2021 · HL
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,341,858
UG3 · FY2020 · HL
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$370,684
U01 · FY2014 · HL
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$2,118,888
U01 · FY2012 · HL
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$2,126,770
U01 · FY2011 · HL
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$1,240,314
U01 · FY2010 · HL
IL-10 & PD-1 Modulation to Reduce CMV Disease Incidence in Solid Organ Recipients$202,500
R21 · FY2010 · AI
IL-10 & PD-1 Modulation to Reduce CMV Disease Incidence in Solid Organ Recipients$258,000
R21 · FY2009 · AI
CASG 209$380
M01 · FY2007 · RR · contact PI